NCT00557440View on ClinicalTrials.gov

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Asthma
Interventions
DRUG

fluticasone propionate/salmeterol

Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.

DRUG

indacaterol maleate / mometasone furoate

Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.

DRUG

placebo to indacaterol/mometasone

Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.

DRUG

placebo to fluticasone propionate/salmeterol

Placebo to fluticasone propionate / salmeterol delivered via MDDPI.

Trial Locations (6)

Unknown

Novartis Investigator Site, Aalst

Novartis Investigator site, Ghent

Novartis Investigator Site, Berlin

Novartis Investigator Site, Hanover

Novartis Investigator Site, Landsberg

Novartis Investigator Site, Rostock

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00557440 - Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma | Biotech Hunter | Biotech Hunter